Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that interim
results from an investigator-sponsored phase II clinical trial of
ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous
T-cell lymphoma (CTCL) were presented at the Society for Investigative
Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.
ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS
has not been approved for use in CTCL.
The trial enrolled CTCL patients with mycosis fungoides (MF) or Sezary
syndrome. At the time of data analysis, 17 patients had been enrolled,
including 16 with MF and one with Sezary syndrome. Patients had received
a median of six prior therapies, including a median of four prior
systemic therapies. The primary endpoint of the trial is clinical
response rate. Secondary endpoints include correlation of clinical
response with CD30 expression levels, duration of response,
progression-free survival and safety. The study is led by principal
investigator Dr. Youn H. Kim, Professor, Department of Dermatology, and
Director, Multidisciplinary Cutaneous Lymphoma Program at Stanford
University School of Medicine in Stanford, CA. Key findings include: